Nitrite-boosting Therapy for Improving Physiological Function in Patients With Chronic Kidney Disease

Sponsor
University of Colorado, Boulder (Other)
Overall Status
Recruiting
CT.gov ID
NCT03826147
Collaborator
(none)
92
1
2
62
1.5

Study Details

Study Description

Brief Summary

Nitric oxide (NO) is an essential molecule in the body that is decreased in patients with chronic kidney disease (CKD), leading to reductions in vascular, movement ("motor") and cognitive functions. This study will determine if daily oral supplementation (3 months) with a supplement that increases NO in the body, i.e., nitrate-rich beetroot juice, improves vascular, motor and cognitive function in patients with CKD; this study will also provide insight into the biological reasons (mechanisms) by which supplementation with nitrate-rich beetroot juice improves vascular function in these patients. Overall, this research will provide scientific evidence supporting the use of nitrate-rich beetroot juice for preserving physiological function and preventing co-morbid clinical conditions and disability in CKD.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Nitrate-rich beetroot juice
  • Dietary Supplement: Nitrate-depleted beetroot juice
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
92 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
Double-blind
Primary Purpose:
Other
Official Title:
Nitrite-boosting Therapy for Improving Physiological Function in Patients With Chronic Kidney Disease
Actual Study Start Date :
May 1, 2019
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Nitrate-rich beetroot juice

Daily dose of nitrate-rich beetroot juice (70 mL) for 3 months.

Dietary Supplement: Nitrate-rich beetroot juice
Daily supplementation with ~100 kcal of nitrate-rich beetroot juice containing 400 mg of dietary nitrate (James White Drinks, UK).

Placebo Comparator: Nitrate-depleted beetroot juice

Daily dose of nitrate-depleted beetroot juice (70 mL) for 3 months. The nitrate-depleted beetroot juice is identical in appearance, taste and caloric content to nitrate-rich beetroot juice, but with nitrate removed.

Dietary Supplement: Nitrate-depleted beetroot juice
Daily supplementation with ~100 kcal of nitrate-depleted beetroot juice (James White Drinks, UK).

Outcome Measures

Primary Outcome Measures

  1. Change in vascular endothelial function [Baseline, 3 months]

    as measured by brachial artery flow-mediated dilation

  2. Change in aortic stiffness [Baseline, 3 months]

    as measured by carotid-femoral pulse wave velocity

Secondary Outcome Measures

  1. Change in oxidative stress-associated suppression of endothelial function assessed as the increase in brachial artery flow-mediated dilation following an ascorbic acid infusion [Baseline, 3 months]

    The influence of oxidative stress on brachial artery flow-mediated dilation will be determined by infusing a supraphysiological dose of ascorbic acid known to scavenge superoxide or isovolumic saline

  2. Change in endothelial cell markers of oxidative stress [Baseline, 3 months]

    Endothelial cell nitrotyrosine levels will be determined

Other Outcome Measures

  1. Motor function composite score [Baseline, 3 months]

    Multiple domains of motor function (including endurance, strength, dexterity) assessed using the NIH Toolbox Motor Battery (aggregated into one reported value)

  2. Fluid cognition composite score [Baseline, 3 months]

    Multiple domains of cognitive function (including executive function, memory, processing speed) assessed using the NIH Toolbox Cognitive Battery (aggregated into one reported value)

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • CKD stage II-IV (eGFR using the Modification of Diet in Renal Disease (MDRD) prediction equation 20-90 mL/min/1.73m2; stable renal function in the past 3 months)

  • Ability to give informed consent

  • Albumin > 3.0 g/dL

  • Ability to perform motor and cognitive tests (e.g., can rise from a chair, walk for 6 min, climb 10 stairs)

  • Free from alcohol dependence or abuse, as defined by the American Psychiatry Association, Diagnostic and Statistical Manual of Mental Disorders (DSM-V)

  • Mini-mental state examination score >21 (rationale: to screen for subjects with major cognitive impairment)

  • Blood pressure (BP) >100/60 mmHg for past 3 months (rationale: blood pressure below 100/60 mmHg may elevate the normally small risk of hypotension with nitrate supplementation)

  • Not taking medications that will interfere with administered medications (e.g., sildenafil interacts with nitroglycerin)

  • Body mass index (BMI) <40 kg/m2 (vascular function measurements can be inaccurate in severely obese patients)

Exclusion Criteria:
  • Life expectancy <1 year

  • Uncontrolled hypertension, defined as blood pressure > 160/100 mmHg in the past 3 months

  • History of severe liver disease

  • History of severe congestive heart failure (i.e., ejection fraction < 35%)

  • History of hospitalizations within the last 3 months

  • Active infection or antibiotic therapy

  • Warfarin use

  • Vasculitis requiring immunosuppressive therapy within the last year

  • High dietary nitrate intake or current nitrate/nitrite supplementation; hypersensitivity to nitrates or nitrites

  • Glucose-6-phosphate dehydrogenase deficiency or blood methemoglobin >2%

  • Unwilling to abstain from use of mouthwash or other oral hygiene practices (e.g., tongue scraping) outside of teeth brushing that disrupt the oral microbiome and would interfere with nitrate conversion to nitrite

  • Blood donation within 8 weeks prior to enrolling in the study; unwilling to abstain from donating blood for 8 weeks after completing the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Integrative Physiology of Aging Laboratory Boulder Colorado United States 80309

Sponsors and Collaborators

  • University of Colorado, Boulder

Investigators

  • Principal Investigator: Matthew J Rossman, PhD, University of Colorado, Boulder

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Douglas Seals, Professor, University of Colorado, Boulder
ClinicalTrials.gov Identifier:
NCT03826147
Other Study ID Numbers:
  • 18-0364
First Posted:
Feb 1, 2019
Last Update Posted:
Jul 21, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 21, 2022